Won't allow sale of Coronil without certification: Maharashtra minister

Without naming anyone, Mr Deshmukh said on Twitter that it was "highly deplorable" that two senior Union ministers endorsed the drug

Coronil launch
Yoga guru Ramdev flanked by Union ministers Harsh Vardhan (left) and Nitin Gadkari at last week’s launch of Coronil PTI
Press Trust of India Mumbai
2 min read Last Updated : Feb 23 2021 | 7:35 PM IST

The sale of Coronil tablets of

Patanjali will not be allowed in Maharashtra without "proper certification", state Home Minister Anil Deshmukh said on Tuesday.

The statement came a day after the Indian Medical Association (IMA) expressed shock over the "blatant lie of WHO certification" for Coronil tablets which Patanjali claims is an evidence-based medicine to fight COVID-19.

While the IMA also demanded an explanation from Union Health Minister Harsh Vardhan in whose presence the medicine was launched, the World Health Organization clarified that it had not reviewed or certified the effectiveness of any traditional medicine for the treatment of COVID-19.

Without naming anyone, Deshmukh said on Twitter that it was "highly deplorable" that two senior Union ministers endorsed the drug.

"The #IMA has questioned the said 'clinical trials' of #Coronil & WHO refuted the false claims made by #Patanjali Ayurveda for giving any certificate regarding its effectiveness for #Covid19 treatment," Deshmukh said.

"...selling of #Coronil without proper certification from competent health organizations like #WHO, #IMA and others will not be allowed in Maharashtra," the minister said.

Yoga guru Ramdev's Patanjali Ayurved had on February 19 said the Coronil tablet had received certification from the Ayush Ministry as a medicine supporting COVID-19 treatment as per the WHO's certification scheme.

However, Patanjali's managing director Acharya Balkrishna later said "We want to clarify to avoid confusion that our WHO GMP compliant COPP certificate to Coronil is issued by DCGI, Government of India" and "WHO do not approve or disapprove any drugs".

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusMaharashtraPatanjali

First Published: Feb 23 2021 | 7:31 PM IST

Next Story